Literature DB >> 23411039

Association between baseline lipoprotein (a) levels and restenosis after coronary stenting: meta-analysis of 9 cohort studies.

Shan-yu Qin1, Jie Liu, Hai-xing Jiang, Bang-li Hu, You Zhou, Vesa M Olkkonen.   

Abstract

BACKGROUND: Previous studies have shown inconsistent results on the association between baseline plasma Lipoprotein (a) [Lp(a)] levels and in-stent restenosis (ISR) after coronary stenting.
OBJECTIVE: We conducted a meta-analysis of observational studies to assess the association between baseline Lp(a) levels and the restenosis after successful coronary stenting.
METHODS: We searched for studies without language restriction in PubMed, Embase, Cochrane library, Ovid library database prior to October 2012. Random-effects method was applied to estimate the pooled standard mean difference (SMD). Heterogeneity, sensitivity and subgroup analysis were used to evaluate the results. Meta-regression analysis was employed to investigate sources of heterogeneity.
RESULTS: 9 cohort studies including 1834 patients (600 ISR and 1234 no-ISR patients) were eligible for our analysis. Overall, we found significantly elevated baseline Lp(a) levels in ISR (in-stent restenosis) patients (SMD = 0.42, 95% CI: 0.14-0.71, P = 0.003). High heterogeneity existed between the individual studies (P < 0.001, I(2) = 86.9%). The association was stronger in the Asian population than the overall association found. Further, similar observations were made in the subgroup with drug-eluting stent and the group in which Lp(a) was assayed by immunoturbidimetry. Multivariable regression analysis suggested that ethnicity was the major source of heterogeneity in the data (P = 0.036).
CONCLUSIONS: Our meta-analysis suggests that significantly elevated baseline plasma Lp(a) level is associated with ISR. The Lp(a) level appears to be a good predictor of ISR, especially in the Asian population or patients who received drug-eluting stent implantation. Further research is warranted to evaluate the association by taking the ethnicity and type of stent into account.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23411039     DOI: 10.1016/j.atherosclerosis.2013.01.014

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  5 in total

1.  Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Weihua Guan; Jing Cao; Brian T Steffen; Wendy S Post; James H Stein; Mathew C Tattersall; Joel D Kaufman; Joseph P McConnell; Daniel M Hoefner; Russell Warnick; Michael Y Tsai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-02-19       Impact factor: 8.311

2.  Lipid Metabolism Disorders.

Authors:  Christian Marx
Journal:  Dtsch Arztebl Int       Date:  2022-04-01       Impact factor: 8.251

Review 3.  Lipoprotein(a): An independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction.

Authors:  Enas A Enas; Basil Varkey; T S Dharmarajan; Guillaume Pare; Vinay K Bahl
Journal:  Indian Heart J       Date:  2019-03-20

Review 4.  The relationship between Lp(a) and CVD outcomes: a systematic review.

Authors:  Carol A Forbes; Ruben G W Quek; Sohan Deshpande; Gill Worthy; Robert Wolff; Lisa Stirk; Jos Kleijnen; Shravanthi R Gandra; Stephen Djedjos; Nathan D Wong
Journal:  Lipids Health Dis       Date:  2016-05-17       Impact factor: 3.876

Review 5.  Lipoprotein(a)-The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation.

Authors:  Sabina Ugovšek; Miran Šebeštjen
Journal:  Biomolecules       Date:  2021-12-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.